20
Views
10
CrossRef citations to date
0
Altmetric
Original Article

Comparative vestibular toxicity of dibekacin, habekacin and cisplatin

&
Pages 315-321 | Published online: 08 Jul 2009
 

Abstract

The vestibular toxicity of two aminoglycoside antibiotics, dibekacin sulfate and habekacin sulfate, and of a drug with potent antimitotic activity, cisplatin (cis-diamminedichloroplatinum) has been investigated in both rats and frogs. In rats, chronic intraperitoneal injection of a saline solution of dibekacin (50 mg/kg/day), habekacin (50 mg/kg/day), cisplatin (0.5 mg/kg/day) for 4 weeks and of cisplatin (1 mg/kg/day) for 5 weeks, produced no behavioral vestibular disorders and the righting reflex could be elicited at any time. In frogs, the spontaneous discharge was recorded from individual fibres of the ampullary nerve of the horizontal semicircular canal before and after acute administration of the drugs, dissolved in Ringer, into the perilymph of the inner ear near the horizontal ampulla. Following injection of 1 μl of solutions containing 10 μg or 20 μg of dibekacin, 20 μg or 50 μg of habekacin, 0.5 μg, 2.5 μg or 10 μg of cisplatin, the spontaneous discharge decreased in a number of fibres and was sometimes completely abolished. The vestibular toxicity of the three drugs tested is discussed with respect to that of aminosides whose ototoxicity is well known.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.